Day 2 Coverage of ENDO 2015

Posted on March 6, 2015 by MaryO

ENDO_2015

 

OR22-Osteoporosis–Winner: Outstanding Abstract Award

Effects of teriparatide on bone microarchitecture in postmenopausal women with osteoporosis
S Orlov, R Ridout, L Tile, M Kapral, S Cardew, MR Werb, SD Sandler, J Chang, H Hu, E Szabo, C Derzko, A Cheung

FRI 224-247-Metabolic and Genetic Bone Disorders

The effect of vitamin D supplementation on falls and physical performance in elderly women. A randomized clinical trial
S Yousefian, JC Gallagher, SH Tella

The etiology and risk factors analysis in hypercalcemic crisis
H Liao, DL Lorber, E Cohen

LBF 001-014-Late-breaking Thyroid/HPT Axis II

Diagnostic lobectomy for thyroid nodules >4 cm with benign cytology after fine-needle aspiration is associated with improved outcomes at an acceptable cost compared to observation: …
L Lee, E Theodosopoulos, EJ Mitmaker, JA Lee, J Chabot, JH Kuo

LBF 015-023-Late-breaking Reproductive Endocrinology II

Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes
EJ Gianatti, R Hoermann, Q Lam, P Dupuis, JD Zajac, M Grossmann

OR17-Novel Aspects of Adrenal Tumors and the HPA Axis

Epigenetic modulation of DNA Is associated with fatigue, depression and anxiety in patients with Cushing’s syndrome in remission: A genome-wide methylation study
CAM Glad, JC Andersson-Assarsson, P Berglund, R Bergthorsdottir, O Ragnarsson, G Johannsson

Pharmacogenetic analysis of glucocorticoid gene polymorphisms and prediction of daily dexamethasone doses in adults with congenital adrenal hyperplasia
JS Frassei, LG Gomes, RP Moreira, G Madureira, BB Mendonca, TA Bachega

OR20-Pituitary Tumors-New Clinical Considerations

Reduced mortality in patients with GH replacement therapy – a Swedish study based on more than 4,000 patient-years
DS Olsson, AG Nilsson, P Trimpou, B-A Bengtsson, E Andersson, G Johannsson

OR22-Osteoporosis

Denosumab restores cortical bone loss at the 1/3 radius associated with aging and reduces wrist fracture risk: Analyses from the Freedom extension cross-over group
JP Bilezikian, CL Benhamou, CJF Lin, JP Brown, NS Daizadeh, PR Ebeling, A Fahrleitner-Pammer, E Franek, N Gilchrist, PD Miller, JA Simon1, I Valter, AF Zerbini, C Libanati

OR22-Osteoporosis–Winner Clinical Fellows Abstract Award Travel Grants in Womens Health

Estrone may be more important than testosterone and estradiol for bone health and prevention of fractures in post-menopausal women
G Toraldo, TG Travison, X Zhang, KE Broe, S Bhasin, DP Kiel, AD Coviello

Filed under: adrenal, Clinical trials, growth hormone, Meetings and Conferences, pituitary, Rare Diseases, Treatments | Tagged: , , , , , , , , , , , , | Leave a comment »

Cortisol Dysregulation and Alcoholism: Consequence, Correlation or Causality?

Posted on March 6, 2015 by MaryO

What

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, announces that Gary S. Wand, M.D., will deliver the 7th Annual Jack Mendelson Honorary Lecture. Dr. Wand is an internationally recognized neuroendocrinologist and the inaugural Rivière Professor in Endocrinology and Metabolism at The Johns Hopkins University School of Medicine. The title of his presentation is “Cortisol Dysregulation and Alcoholism: Consequence, Correlation or Causality?”

Who

Dr. Wand’s research has advanced our understanding of the genetic and environmental determinants of the stress response and has elucidated how excessive stress hormone production may contribute to neurobiological conditions such as alcohol or drug disorders.

Some of Dr. Wand’s seminal discoveries include identifying unique pharmacological responses to naloxone in individuals at increased risk for alcohol use disorders, identifying specific hormonal responses in subjects with alcohol use disorders, and characterizing human brain neurochemical changes using imaging in subjects with substance use disorders.

Dr. Wand is studying the epigenetic modulation of stress and cortisol exposure in rodent and human models, based on the hypothesis that specific epigenetic events affect how much cortisol an individual produces, which in turn influences dopamine transmission.

Dr. Wand received his medical degree and subsequent training in internal medicine from the George Washington University. Following post-doctoral training in Endocrinology and Metabolism at The Johns Hopkins University School of Medicine, he was a fellow in the peptide laboratories of Richard Mains, Ph.D. and Betty Eipper, Ph.D. in JHU’s Department of Neuroscience. Dr. Wand then joined the faculty of the Johns Hopkins University School of Medicine.

In 2000, NIAAA and the NIH honored Dr. Wand with a 10-year Merit Award to continue his research on the role of the HPA axis in alcoholism. He has also received numerous local and national “Best Doctor” awards. Dr. Wand is the author of more than 175 articles and chapters and is on the editorial board of several journals.

When

Thursday, March 19th at 1:30 p.m. EDT

Where

Masur Auditorium, NIH Building 10, Bethesda, Maryland

Background

NIAAA established the Jack Mendelson Honorary Lecture Series as a tribute to Dr. Jack Mendelson, who made remarkable scientific contributions to the field of clinical alcohol research. The purpose of this honorary lecture series is to highlight clinical/human research in the alcohol field by an outstanding investigator who has made significant and long-term contributions to our understanding of alcoholism susceptibility, alcohol’s effects on the brain and other organs, and the prevention and treatment of alcohol use disorders. NIAAA is pleased to present this series of scientific lectures to acknowledge the advances researchers are making in a wide range of alcohol-related areas of clinical research, and to honor the memory of an individual whose exciting and pioneering research with human alcoholics remains relevant today.

For additional information about the lecture see: http://www.niaaa.nih.gov/about-niaaa/our-work/research-portfolio/projects-initiatives/keller-and-mendelson-honorary-lecture

The Mendelson Honorary Lecture is free and open to the public. Sign language interpreters will be provided. For other reasonable accommodations or further information call Joanna Mayo, 301-443-3860, or visit www.niaaa.nih.gov. For TTY callers, please call the above number through the Federal Relay Service at 1-800-877-8339.

The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health, is the primary U.S. agency for conducting and supporting research on the causes, consequences, prevention, and treatment of alcohol abuse, alcoholism, and alcohol problems. NIAAA also disseminates research findings to general, professional, and academic audiences. Additional alcohol research information and publications are available at http://www.niaaa.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Filed under: Meetings and Conferences, Rare Diseases | Tagged: , , , , , | Leave a comment »

Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing’s Syndrome at the 97th Annual Endocrine Society Meeting – MarketWatch

Posted on March 6, 2015 by MaryO

ENDO_2015

 

Corcept Therapeutics Incorporated CORT,  a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that a variety of posters about Korlym(R) (mifepristone) will be presented at the 97th annual Endocrine Society Meeting (ENDO 2015) being held at the San Diego Convention Center from March 5 – 7, 2015.

“We are pleased to see the breadth of new data being presented at ENDO 2015 about Korlym (mifepristone), which adds to the already substantial literature describing the use of mifepristone to treat Cushing’s Syndrome,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “We are committed to bringing innovative therapies to patients in need, and we look forward to continuing our pivotal role in advancing the scientific understanding of Cushing’s syndrome and other rare and debilitating diseases.”

Multiple endocrinologists, researchers and centers of excellence are presenting a total of nine abstracts.

Read the entire article at Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing’s Syndrome at the 97th Annual Endocrine Society Meeting – MarketWatch.

Filed under: Cushing's, Meetings and Conferences, pituitary, Rare Diseases, Treatments | Tagged: , , , , | Leave a comment »

Day 1 Coverage of ENDO 2015

Posted on March 5, 2015 by MaryO

ENDO_2015

 

Late-breaking Neuroendocrinology and Pituitary I

6-month interim safety and efficacy of different dose levels of TransCon HGH administered once weekly versus standard daily human growth hormone replacement therapy in pre-pubertal children with GHD
P Chatelain, O Malievsky, K Radziuk, HH Elsedfy, E Mikhailova, M Beckert

OR01-Clinical Issues in Type 1 and Type 2 Diabetes

Metformin as an adjunct therapy does not improve glycemic control among overweight adolescents with type 1 diabetes (T1D)
I Libman, KM Miller, LA DiMeglio, K Bethin, ML Katz, A Shah, JH Simmons, MJ Haller, S Raman, WV Tamborlane, J Coffey, AM Saenz, RW Beck

Patient-reported outcomes 1 year after randomization to laparoscopic adjustable gastric banding or intensive weight and diabetes management in obese patients with type 2 diabetes mellitus
DC Simonson, SA Ding, F Halperin, M Wewalka, K Foster, K Kelly, J Panosian, A Goebel-Fabbri, O Hamdy, K Clancy, D Lautz, A Vernon, AB Goldfine

Undermanagement of hyperlipidemia in young persons with type 1 diabetes (T1D)
ML Katz, GH Telo, JB Cartaya, CE Dougher, M Ding, LM Laffel

OR01-Clinical Issues in Type 1 and Type 2 Diabetes–Winner: Outstanding Abstract Award

18F-Flouride PET/CT and 18F-FDG labeled autologous leukocyte PET/CT for diagnosis of osteomyelitis in diabetic Charcot’s neuroarthropathy of foot
A Rastogi, A Bhansali

OR11-Thyroid Development, Clinical and Autoimmunity

Long-term outcomes and predictive factors of efficacy of ultrasound-guided ethanol injection for benign cystic thyroid lesions
E Papini, R Guglielmi, I Misischi, FM Graziano, A Persichetti, R Rendina, S Taccogna, G Bizzarri

OR11-Thyroid Development, Clinical and Autoimmunity–Winner: Outstanding Abstract Award

Novel insights into the effects of maternal thyroid function on child IQ reveal detrimental effects of high FT4 levels
TIM Korevaar, M Medici, H Tiemeier, E Visser, TJ Visser, RP Peeters

Oral Presentations in Reproductive Science–Winner: Oral Abstract Award in Reproductive Science

Kisspeptin signaling in the amygdala modulates reproductive hormone secretion
AN Comninos, J Anastasovska, M Sahuri-Arisoylu, X Feng Li, S Li, M Hu, CN Jayasena1, MA Ghatei, SR Bloom, P Matthews, K O’Byrne, JD Bell, WS Dhillo

PP09-Acromegaly

Biochemical control is maintained with pasireotide LAR in patients with acromegaly: Results from the extension of a randomized phase III study (PAOLA)
MR Gadelha, MD Bronstein, T Brue, MG Coculescu, L De Marinis, M Fleseriu, M Guitelman, V Pronin, G Raverot, I Shimon, J Fleck, A Kandra, AM Pedroncelli, A Colao

THR 113-137-Testis Cells: Control, Regulation and Functions

Effects of testosterone level on lower urinary tract symptoms
ED Crawford, W Poage, A Nyhuis, DA Price, SA Dowsett, D Muram

Filed under: Meetings and Conferences, pituitary, Rare Diseases, Treatments | Tagged: , , , , , , , , , , , , , , , | Leave a comment »

Screening for Cushing’s syndrome: Is it worthwhile?

Posted on March 5, 2015 by MaryO

The data suggests that Cushing is not frequent enough to support the use of routine screening in patients with morbid obesity and type 2 DM. Also only 1 % of hypertensive patients have secondary hypertension due to CS. However, screening should be considered in young patients with resistant DM and/or hypertension. Among patients with osteoporosis and vertebral fractures up to 5 % were diagnosed with subclinical hypercortisolism; most of these had adrenal adenoma. Screening for CS is important in subjects with adrenal incidentaloma, and many studies show a high prevalence (~10 %) of Cushing or subclinical CS in these patients.

Abstract

Introduction

Cushing’s syndrome (CS) is a rare disease characterized by a collection of signs and symptoms, also common in the general population without elevated cortisol secretion. During the last years more patients with CS are identified earlier and with milder disease. Many of these patients are diagnosed during screening efforts performed for certain or isolated complaints like weight gain, diabetes mellitus (DM), hypertension, osteoporosis, elevated white blood cell counts and more.

Methods

In this review article the most popular screening test performed in the studies cited was the 1-mg dexamethasone suppression test.

Conclusions

Cushing is not frequent enough to support the use of routine screening in patients with morbid obesity and type 2 DM. Also only 1 % of hypertensive patients have secondary hypertension due to CS. However, screening should be considered in young patients with resistant DM and/or hypertension. Among patients with osteoporosis and vertebral fractures up to 5 % were diagnosed with subclinical hypercortisolism; most of these had adrenal adenoma. Screening for CS is important in subjects with adrenal incidentaloma, and many studies show a high prevalence (~10 %) of Cushing or subclinical CS in these patients.

Buy this article for $39.00 at http://link.springer.com/article/10.1007%2Fs11102-015-0634-9

Filed under: adrenal, Cushing's | Tagged: , , , , , , , , , , , | Leave a comment »

« Previous Page — Next Page »